These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 11958690)

  • 1. Analysis of a primary isolate-like virus from simian and human immunodeficiency virus-infected macaque having broad neutralizing activity.
    Miyazaki Y; Kuwata T; Takehisa J; Hayami M
    AIDS Res Hum Retroviruses; 2002 Apr; 18(6):469-75. PubMed ID: 11958690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of Broadly Neutralizing Antibodies and Their Mapping by Monomeric gp120 in Human Immunodeficiency Virus Type 1-Infected Humans and Simian-Human Immunodeficiency Virus SHIVSF162P3N-Infected Macaques.
    Jia M; Lu H; Markowitz M; Cheng-Mayer C; Wu X
    J Virol; 2016 Apr; 90(8):4017-4031. PubMed ID: 26842476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protective Efficacy of Broadly Neutralizing Antibodies with Incomplete Neutralization Activity against Simian-Human Immunodeficiency Virus in Rhesus Monkeys.
    Julg B; Sok D; Schmidt SD; Abbink P; Newman RM; Broge T; Linde C; Nkolola J; Le K; Su D; Torabi J; Pack M; Pegu A; Allen TM; Mascola JR; Burton DR; Barouch DH
    J Virol; 2017 Oct; 91(20):. PubMed ID: 28768869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gp120 V5 Is Targeted by the First Wave of Sequential Neutralizing Antibodies in SHIV
    Jia M; Lu H; Kong XP; Cheng-Mayer C; Wu X
    Viruses; 2018 May; 10(5):. PubMed ID: 29772652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomic and biological alteration of a human immunodeficiency virus type 1 (HIV-1)-simian immunodeficiency virus strain mac chimera, with HIV-1 Env, recovered from a long-term carrier monkey.
    Igarashi T; Kuwata T; Takehisa J; Ibuki K; Shibata R; Mukai R; Komatsu T; Adachi A; Ido E; Hayami M
    J Gen Virol; 1996 Aug; 77 ( Pt 8)():1649-58. PubMed ID: 8760411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of neutralizing antibodies against tier 2 human immunodeficiency virus 1 in rhesus macaques infected with tier 1B simian/human immunodeficiency virus.
    Himeno A; Ishida Y; Mori H; Matsuura K; Kikukawa M; Sakawaki H; Miura T
    Arch Virol; 2019 May; 164(5):1297-1308. PubMed ID: 30820667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccination of rhesus macaques with recombinant Mycobacterium bovis bacillus Calmette-Guérin Env V3 elicits neutralizing antibody-mediated protection against simian-human immunodeficiency virus with a homologous but not a heterologous V3 motif.
    Someya K; Cecilia D; Ami Y; Nakasone T; Matsuo K; Burda S; Yamamoto H; Yoshino N; Kaizu M; Ando S; Okuda K; Zolla-Pazner S; Yamazaki S; Yamamoto N; Honda M
    J Virol; 2005 Feb; 79(3):1452-62. PubMed ID: 15650171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neutralization sensitivity of a simian-human immunodeficiency virus (SHIV-HXBc2P 3.2N) isolated from an infected rhesus macaque with neurological disease.
    Song B; Cayabyab M; Phan N; Wang L; Axthelm MK; Letvin NL; Sodroski JG
    Virology; 2004 Apr; 322(1):168-81. PubMed ID: 15063126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neutralizing antibodies in sera from macaques infected with chimeric simian-human immunodeficiency virus containing the envelope glycoproteins of either a laboratory-adapted variant or a primary isolate of human immunodeficiency virus type 1.
    Montefiori DC; Reimann KA; Wyand MS; Manson K; Lewis MG; Collman RG; Sodroski JG; Bolognesi DP; Letvin NL
    J Virol; 1998 Apr; 72(4):3427-31. PubMed ID: 9525675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of broad neutralization activity in simian/human immunodeficiency virus-infected rhesus macaques after long-term infection.
    Gao N; Wang W; Wang C; Gu T; Guo R; Yu B; Kong W; Qin C; Giorgi EE; Chen Z; Townsley S; Hu SL; Yu X; Gao F
    AIDS; 2018 Mar; 32(5):555-563. PubMed ID: 29239895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infection of macaques with chimeric simian and human immunodeficiency viruses containing Env from subtype F.
    Kuwata T; Takemura T; Takehisa J; Miura T; Hayami M
    Arch Virol; 2002 Jun; 147(6):1121-32. PubMed ID: 12111423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of primary isolate-like variants of simian-human immunodeficiency virus.
    Crawford JM; Earl PL; Moss B; Reimann KA; Wyand MS; Manson KH; Bilska M; Zhou JT; Pauza CD; Parren PW; Burton DR; Sodroski JG; Letvin NL; Montefiori DC
    J Virol; 1999 Dec; 73(12):10199-207. PubMed ID: 10559336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterologous neutralizing antibody induction in a simian-human immunodeficiency virus primate model: lack of original antigenic sin.
    Rasmussen RA; Montefiori DC; Robinson HL; McClure HM; Ruprecht RM
    J Infect Dis; 2001 Dec; 184(12):1603-7. PubMed ID: 11740737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection.
    Baba TW; Liska V; Hofmann-Lehmann R; Vlasak J; Xu W; Ayehunie S; Cavacini LA; Posner MR; Katinger H; Stiegler G; Bernacky BJ; Rizvi TA; Schmidt R; Hill LR; Keeling ME; Lu Y; Wright JE; Chou TC; Ruprecht RM
    Nat Med; 2000 Feb; 6(2):200-6. PubMed ID: 10655110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SIV/HIV Nef recombinant virus (SHIVnef) produces simian AIDS in rhesus macaques.
    Mandell CP; Reyes RA; Cho K; Sawai ET; Fang AL; Schmidt KA; Luciw PA
    Virology; 1999 Dec; 265(2):235-51. PubMed ID: 10600596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of Antibodies with Broad Neutralization Specificities against HIV-1 after Long Term SHIV Infection in Macaques.
    Gao N; Gai Y; Meng L; Wang C; Zhang X; Wang W; Qin C; Yu X; Gao F
    Viruses; 2020 Jan; 12(2):. PubMed ID: 32023860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies.
    Mascola JR; Stiegler G; VanCott TC; Katinger H; Carpenter CB; Hanson CE; Beary H; Hayes D; Frankel SS; Birx DL; Lewis MG
    Nat Med; 2000 Feb; 6(2):207-10. PubMed ID: 10655111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of a neutralization-escape variant of SHIVKU-1, a virus that causes acquired immune deficiency syndrome in pig-tailed macaques.
    Narayan SV; Mukherjee S; Jia F; Li Z; Wang C; Foresman L; McCormick-Davis C; Stephens EB; Joag SV; Narayan O
    Virology; 1999 Mar; 256(1):54-63. PubMed ID: 10087226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of immune responses induced by HIV-1 gp120 in rhesus macaques: effect of vaccination on challenge with pathogenic strains of homologous and heterologous simian human immunodeficiency viruses.
    Kumar A; Lifson JD; Silverstein PS; Jia F; Sheffer D; Li Z; Narayan O
    Virology; 2000 Aug; 274(1):149-64. PubMed ID: 10936096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determination of a statistically valid neutralization titer in plasma that confers protection against simian-human immunodeficiency virus challenge following passive transfer of high-titered neutralizing antibodies.
    Nishimura Y; Igarashi T; Haigwood N; Sadjadpour R; Plishka RJ; Buckler-White A; Shibata R; Martin MA
    J Virol; 2002 Mar; 76(5):2123-30. PubMed ID: 11836389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.